Author Archives: Jill Wechsler

FDA Releases Three Biosimilar Development Guidelines

After months of anticipation, the Food and Drug Administration issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies. The announcement came the same day that FDA officials discussed new user fees for biosimilars and generic drugs at a Congressional hearing. Three separate draft guidances map out the scientific considerations, quality [...]
Posted in Regulatory | Tagged , , , , , | Leave a comment